^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    GZ402663

    i
    Other names: GZ402663, sFLT01, anti vascular endothelial growth factor (VEGF) gene therapy, AAV2sFLT 01, AAV2-sFLT01, GZ-402663
    Associations

    News

    Trials
    Company:
    AGTC, Sanofi
    Drug class:
    VEGF-A inhibitor, PIGF inhibitor, Gene transference
    Related drugs:
    Associations

    News

    Trials
    over3years
    sFLT01 modulates invasion and metastasis in prostate cancer DU145 cells by inhibition of VEGF/GRP78/MMP2&9 axis. (PubMed, BMC Mol Cell Biol)
    Overall, these data indicated that the inhibitory impact of sFLT01 on cancer cells growth and invasiveness could be mediated through the modulation of VEGF/GRP78/MMP2&9 axis and activation of TIMPs.
    Journal
    |
    MMP2 (Matrix metallopeptidase 2) • TIMP1 (Tissue inhibitor of metalloproteinases 1) • HSPA5 (Heat Shock Protein Family A (Hsp70) Member 5) • MMP9 (Matrix metallopeptidase 9)
    |
    KIM1 expression • TIMP1 expression • MMP9 elevation
    |
    GZ402663